Akut non-lenfobiastik lösemi ve myelodisplastik sendrom ile kronik myelositik löseminin akut blastik dönüşüm fazında düşük doz cytosine arabinoside uygulaması
Loading...
Files
Date
1992-12-31
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Son yıllarda akut non-lenfoblastik lösemi (ANLL) ve myelodisplastik sendrom (MDS) ile kronik myelositik löseminin (KML) akut myeloblastik dönüşüm fazındaki olgularda düşük doz cytosine arabinoside (ARA-C) tedavisi ile alınan sonuçların ümit verici olduğu bildirilmektedir. Bu çalışmada da 21 ANLL 'li ve 8 KML 'li akut myeloblastik dönüşüm fazındaki olgu ile 2 MDS'li olguda (refrakter anemi ve blast fazlalığı) düşük doz ARA-C uygulandı. 21 ANLL 'li olgunun % 28. 6'sında tam remisyon, 8 KML-blastik dönüşümlü olgunun 3 'ünde ise kısmi remisyon elde edilebilir. MDS'Iu olgularda remisyon elde edilmemiş olmakla birlikte, bulguların tümünde transfüzyon ihtiyacı belirgin olarak azaldı. Bütün olguların tedaviye tahammülleri çok iyi oldu ve daha da önemlisi remisyon elde edilemeyenler de yaşam kalitelerinin belirgin olarak yükseldiği gözlendi.
In recent years, therapy with low dose cytosine arabinoside in acute non lymphoblastic leukemia (ANLL) and myelodysplastic syndrome and in patients with blastic transformation phase of chronic myeloid leukemia (CML-B) is reported to be promising. In this study law dose ARA-C is performed in 21 ANLL and 8 CML with acute myeloblastic transformatian and 2 MDS (with refractory anemia and excess blast) cases. Complete Remission is achieved in 28 % of 21 ANLL cases, partial remission is achieved in 3 of 8 CML blastic transformation cases. In cases with MDS remission is not achieved bul in all cases the need for transfusion is decreased significantly. Tolerance to the therapy was very well in all cases and more importantly life quality was increased among patients in which complete remission can not be achieved.
In recent years, therapy with low dose cytosine arabinoside in acute non lymphoblastic leukemia (ANLL) and myelodysplastic syndrome and in patients with blastic transformation phase of chronic myeloid leukemia (CML-B) is reported to be promising. In this study law dose ARA-C is performed in 21 ANLL and 8 CML with acute myeloblastic transformatian and 2 MDS (with refractory anemia and excess blast) cases. Complete Remission is achieved in 28 % of 21 ANLL cases, partial remission is achieved in 3 of 8 CML blastic transformation cases. In cases with MDS remission is not achieved bul in all cases the need for transfusion is decreased significantly. Tolerance to the therapy was very well in all cases and more importantly life quality was increased among patients in which complete remission can not be achieved.
Description
Keywords
Akut non-lenfobiastik lösemi, Myelodisplastik sendrom, Kronik myelositik löseminin akut blastik dönüşüm fazı, Cytosine arabinoside, Acute non-lymphoblastik leukemia, Myelodysplastic syndrome
Citation
Manavoğlu, O. (1993). ''Akut non-lenfobiastik lösemi ve myelodisplastik sendrom ile kronik myelositik löseminin akut blastik dönüşüm fazında düşük doz cytosine arabinoside uygulaması''. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 20(3), 237-241.